03/17/23 3:20 AMNasdaq : BPTS low floatBiophytis Announces Ratio Change Under its American Depositary Receipt (“ADR”) ProgramBiophytis SA (NasdaqCM:BPTS, Euronext Growth Paris:ALBPS) (the "Company" or "Biophytis"), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging,RHEA-AIneutral
03/09/23 2:20 AMNasdaq : BPTS conferencesclinical triallow floatBiophytis To Present Positive Results of Phase 2-3 COVA Study At ERS 2023 21st Lung Science ConferenceBiophytis SA (NASDAQ:BPTS)(Euronext Growth Paris:ALBPS) (the "Company" or "Biophytis"), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging,RHEA-AIneutral
03/02/23 2:00 AMNasdaq : BPTS covid-19low floatBiophytis Announces the Signature of a Master Service Agreement With Intsel Chimos, a Pharmaceutical Company That Will Operate Sarconeos (BIO101) in France for the Treatment of Severe Forms of COVID-19Biophytis and Intsel Chimos signed a master service agreement under which Intsel Chimos will be the operating pharmaceutical company/exploitant, partner and distributor in France for the drug Sarconeos (BIO101) developed by Biophytis in the context of the early access program application. TheRHEA-AIneutral
02/27/23 2:20 AMNasdaq : BPTS covid-19low floatBiophytis Initiates the Regulatory Process for an Early Access Authorization in France from the French National Authority for Health (HAS) for the Treatment with Sarconeos (BIO101) of Severe Forms of COVID-19Biophytis to present the early access application in France at a pre-filing meeting in March with the HAS Biophytis plans to file the application shortly after with the objective of obtaining early access authorization in France in the second quarter of 2023 Biophytis is pursuing in parallel theRHEA-AIneutral
02/23/23 2:20 AMNasdaq : BPTS conferenceslow floatBiophytis To Host a Combined General Shareholder’s Meeting on March 30, 2023Biophytis SA (NasdaqCM:BPTS, Euronext Growth Paris: ALBPS) (the "Company" orRHEA-AIneutral
02/02/23 2:20 AMNasdaq : BPTS clinical trialcovid-19low floatBiophytis Announces Positive Final Results of the Phase 2-3 COVA Study with Sarconeos (BIO101) in Severe COVID-19RHEA-AIneutral
01/31/23 2:20 AMNasdaq : BPTS earningslow floatBiophytis Publishes its Financial Results for the First Half of 2022Biophytis SA (NasdaqCM:BPTS, Euronext Growth Paris:ALBPS),RHEA-AIvery negative
01/19/23 2:00 AMNasdaq : BPTS low floatBiophytis: Judgment of the Paris Court of Appeal of 17 January 2023 in the Case Between Biophytis and Negma Group LtdBiophytis SA (NasdaqCM:BPTS)(Euronext Growth Paris:ALBPS) (the "Company" or "Biophytis"), a clinical-stage biotechnology companyRHEA-AIneutral
01/12/23 2:20 AMNasdaq : BPTS low floatBiophytis To Take Appropriate Measures After Receiving Nasdaq Deficiency NoticeBiophytis SA (NasdaqCM:BPTS)(Euronext Growth Paris:ALBPS) (the "Company" or "Biophytis"), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging,RHEA-AIneutral
01/05/23 2:20 AMNasdaq : BPTS low floatBiophytis Announces Its Participation in Two Major Investor Conferences in January, In the United States and In France: The JP Morgan Healthcare Conference and The Invest Securities BiomedBiophytis SA (NasdaqCM:BPTS, Euronext Growth Paris:ALBPS), ("Biophytis" or the "company") a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging,RHEA-AIneutral